JCM Figure table search 04
Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Tang, P.
Right arrow Articles by Willey, B. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Tang, P.
Right arrow Articles by Willey, B. M.

 Previous Article  |  Next Article 

Journal of Clinical Microbiology, October 2003, p. 4823-4825, Vol. 41, No. 10
0095-1137/03/$08.00+0     DOI: 10.1128/JCM.41.10.4823-4825.2003
Copyright © 2003, American Society for Microbiology. All Rights Reserved.

Investigation of Staphylococcus aureus Isolates Identified as Erythromycin Intermediate by the Vitek-1 System: Comparison with Results Obtained with the Vitek-2 and Phoenix Systems

Patrick Tang,1 Donald E. Low,1 Sandra Atkinson,1 Karen Pike,1 Aisha Ashi-Sulaiman,1 Andrew Simor,2 Susan Richardson,3 and Barbara M. Willey1*

Department of Microbiology, Mount Sinai Hospital, and Toronto Medical Laboratories,1 Department of Microbiology, Sunnybrook and Women's College Health Sciences Centre,2 Department of Pathology and Laboratory Medicine, Hospital for Sick Children, Toronto, Ontario, Canada3

Received 28 February 2003/ Returned for modification 14 May 2003/ Accepted 16 July 2003

We identified 69 Staphylococcus aureus isolates that were erythromycin intermediate as reported by the Vitek-1 system using the GPS-105 card. Of the 57 strains that were available for further testing, all were erythromycin resistant by broth microdilution and the Phoenix system, while the Vitek-2 system identified 55 of 57 strains (96%) as erythromycin resistant. The majority of isolates (54 of 57 [95%]) exhibited the inducible MLS (macrolide-lincosamide-streptogramin family) phenotype, as shown by the double-disk test. We recommend that all S. aureus strains determined as erythromycin intermediate by the Vitek-1 system be interpreted as resistant to erythromycin.

* Corresponding author. Mailing address: Department of Microbiology, Room 1460, Mount Sinai Hospital, 600 University Ave., Toronto, Ontario M5G 1X5, Canada. Phone: (416) 586-3121. Fax: (416) 586-3140. E-mail: bwilley{at}mtsinai.on.ca.

Journal of Clinical Microbiology, October 2003, p. 4823-4825, Vol. 41, No. 10
0095-1137/03/$08.00+0     DOI: 10.1128/JCM.41.10.4823-4825.2003
Copyright © 2003, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:



Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
Antimicrob. Agents Chemother. Clin. Microbiol. Rev.
Clin. Vaccine Immunol. ALL ASM JOURNALS

Copyright © 2003 by the American Society for Microbiology. All rights reserved.